How much does the generic version of Encidipine cost?

Enasidenib is a targeted drug used to treat relapsed or refractory acute myeloid leukemia (AML) harboring IDH2 mutations. It is an oral drug that inhibits the abnormal enzyme activity caused by isocitrate dehydrogenase 2 (IDH2) mutation, thereby interfering with abnormal metabolic pathways and inducing AML cell apoptosis, thereby achieving therapeutic effects.

The price of the generic version of ensidipine is about 2,000 yuan. These generic drugs usually come from countries such as Laos and Bangladesh. They have basically the same ingredients as the original drugs, but the price is relatively affordable. It is worth noting that specific prices may vary by region, supplier and other factors, so when purchasing drugs, patients should choose trustworthy supply channels and pay attention to price changes and make appropriate comparisons.

AML is a hematologic malignancy caused by the uncontrolled proliferation of leukemia stem cells in the bone marrow. Patients usually suffer from anemia, bleeding, infection and other symptoms, which seriously affect the patient's quality of life and prognosis. As a targeted therapy, ensidipine has significant therapeutic potential for the subpopulation of approximately 20% of AML patients who carry IDH2 mutations.

Ensidipine blocks abnormal enzyme activity caused by IDH2 mutations and blocks abnormal metabolic pathways, thereby inducing AML cell apoptosis. This targeted treatment strategy reduces the toxic effects on normal cells and can more effectively reduce the progression of AML and improve survival rates than traditional chemotherapy.

Although ensidipine has demonstrated good efficacy and safety in clinical trials, it is not an ideal treatment option for allAML patients. Currently, the drug is only suitable for specific AML patients carrying IDH2 mutations, so relevant genetic testing is required to determine the patient's mutation status before treatment.

However, it is worth noting that as a new type of targeted drug, the therapeutic potential of ensidipine is still under continuous research and exploration. With the in-depth understanding of the molecular biology of AML and the continuous development of treatment technology, it is believed that this type of targeted drugs will play an increasingly important role in the treatment of AML.